Genzyme and Hospira have entered a new supply agreement under which Hospira’s One 2 One Contract Manufacturing group will fill and package several of Genzyme’s biologics. In May, the FDA finalized the terms of the consent decree regarding quality issues at Genzyme’s Allston, MA manufacturing plant, under which Genzyme paid an upfront disgorgement of past profits of $175 million. Genzyme is also required to move fill/finish operations out of the Allston plant for Cerezyme, Fabrazyme and Thyrog...